| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
5-Bromo-2-iodopyridine is used to prepare substituted (pyridin-3-yl)phenyloxazolidinones as antibacterial agents. The compound has been described as an antibiotic that inhibits the growth of bacteria by binding to the 50S ribosomal subunit. It also interacts with DNA in a triazine ring. The compound does not have a defined pharmacological target of its own but serves as a building block for antibacterial agents.
|
|---|---|
| ln Vitro |
In vitro, 5-bromo-2-iodopyridine is primarily used as a chemical reagent and synthetic intermediate. It is used to prepare substituted (pyridin-3-yl)phenyloxazolidinones as antibacterial agents. The compound is often used in palladium-catalyzed cross-coupling reactions. It serves as a versatile building block in the synthesis of various pharmaceuticals and agrochemicals. It is used in the development of new drugs, particularly those targeting neurological disorders.
|
| ln Vivo |
In vivo activity data for 5-bromo-2-iodopyridine as a therapeutic agent are limited. The compound has been described as an antibiotic that is used to treat bacterial infections, but specific in vivo efficacy and pharmacokinetic data are not well-documented. The compound's in vivo relevance is primarily through its use as a building block for antibacterial agents that are subsequently evaluated in animal models.
|
| Enzyme Assay |
For in vitro chemical synthesis, 5-bromo-2-iodopyridine is used as a versatile building block for palladium-catalyzed cross-coupling reactions. The iodine atom at the 2-position is more reactive than the bromine atom at the 5-position, enabling selective sequential cross-coupling reactions. Standard protocols involve reacting the compound with appropriate coupling partners (boronic acids, alkynes) in the presence of a palladium catalyst and a base.
|
| Cell Assay |
For in vitro cell-based experiments, 5-bromo-2-iodopyridine is used as an intermediate in the synthesis of compounds that are tested in cell viability, proliferation, and cytotoxicity assays. The compound itself is not typically evaluated in cell-based assays. Standard cell culture protocols for test compounds synthesized from this intermediate involve dissolving the final product in DMSO and diluting to working concentrations.
|
| Animal Protocol |
In vivo animal studies using 5-bromo-2-iodopyridine are conducted on the final drug compounds synthesized from it, not on the intermediate itself. For antibacterial agents derived from this building block, efficacy studies would typically be performed in mouse models of bacterial infection. Standard in vivo protocols involve administration to rodents via oral gavage or intraperitoneal injection, with measurement of bacterial burden in target organs.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 5-bromo-2-iodopyridine as a standalone compound are not characterized in the literature. The compound has a molecular weight of 283.89 g/mol, which may limit oral bioavailability. The compound is a solid. Empirical pharmacokinetic data are not available for this intermediate compound.
|
| Toxicity/Toxicokinetics |
5-Bromo-2-iodopyridine is a research chemical and should be handled with appropriate laboratory safety precautions. As a halogenated compound, it may cause skin and eye irritation. The compound should be stored under appropriate conditions. Specific LD₅₀ values, acute toxicity classifications, and chronic toxicity data are not available in the public literature. Standard safety practices include the use of personal protective equipment.
|
| Additional Infomation |
5-Bromo-2-iodopyridine (CAS 223463-13-6) is primarily a research-grade chemical intermediate, not an FDA-approved pharmaceutical drug. Its primary applications are as a versatile building block for the synthesis of pharmaceuticals and agrochemicals. It is used to prepare substituted (pyridin-3-yl)phenyloxazolidinones as antibacterial agents and in the development of drugs targeting neurological disorders. No clinical trials or approved indications exist for this compound.
|
| Molecular Formula |
C5H3BRIN
|
|---|---|
| Molecular Weight |
283.89
|
| Exact Mass |
282.849
|
| CAS # |
223463-13-6
|
| PubChem CID |
593690
|
| Appearance |
Off-white to light brown solid powder
|
| Density |
2.3±0.1 g/cm3
|
| Boiling Point |
258.8±20.0 °C at 760 mmHg
|
| Melting Point |
113-117 °C(lit.)
|
| Flash Point |
110.3±21.8 °C
|
| Vapour Pressure |
0.0±0.5 mmHg at 25°C
|
| Index of Refraction |
1.666
|
| LogP |
2.78
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
8
|
| Complexity |
78.8
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
IC1C([H])=C([H])C(=C([H])N=1)Br
|
| InChi Key |
HSNBRDZXJMPDGH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C5H3BrIN/c6-4-1-2-5(7)8-3-4/h1-3H
|
| Chemical Name |
5-bromo-2-iodopyridine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5225 mL | 17.6125 mL | 35.2249 mL | |
| 5 mM | 0.7045 mL | 3.5225 mL | 7.0450 mL | |
| 10 mM | 0.3522 mL | 1.7612 mL | 3.5225 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
